Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)

被引：32
|
作者：
Diefenbach, Catherine S. [1 ]
Hong, Fangxin [2 ]
David, Kevin A. [3 ]
Cohen, Jonathon [4 ]
Robertson, Michael [5 ]
Advani, Ranjana [6 ]
Palmisiano, Neil D. [7 ]
Ambinder, Richard F. [8 ]
Kahl, Brad S. [9 ]
Ansell, Stephen [10 ]
机构：
[1] NYU Sch Med, NYU Perlmutter Canc Ctr, New York, NY USA
[2] Dana Farber Canc Inst, ECOG ACRIN Biostatist Ctr, Boston, MA USA
[3] Northwestern Univ Feinberg Sch Med, Div Hematol Oncol, Dept Med, Chicago, IL USA
[4] Emory Univ, Atlanta, GA USA
[5] Indiana Univ Sch Med, Indianapolis, IN USA
[6] Stanford Canc Inst, Stanford, CA USA
[7] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA USA
[8] Johns Hopkins Med Inst, Div Hematol Malignancies, SKCCC, Baltimore, MD USA
[9] Washington Univ, St Louis, MO USA
[10] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2016年 / 128卷 / 22期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1182/blood.V128.22.1106.1106
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1106
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512).
    Neal, Joel W.
    Dahlberg, Suzanne Eleanor
    Wakelee, Heather A.
    Aisner, Seena C.
    Bowden, Michaela
    Carbone, David Paul
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing)
    Advani, Ranjana H.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Christian, Beth A.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Ogden, Carol Anne
    Taft, David
    Zak, Daniel E.
    Sacchi, Mariana
    Galderisi, Faith
    Herrera, Alex F.
    BLOOD, 2018, 132
  • [43] Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).
    Appleman, Leonard Joseph
    Puligandla, Maneka
    Pal, Sumanta K.
    Harris, Wayne
    Agarwal, Neeraj
    Costello, Brian Addis
    Ryan, Christopher W.
    Pins, Michael
    Kolesar, Jill
    Vaena, Daniel A.
    Parikh, Rahul Atul
    Hashmi, Mehmood
    Dutcher, Janice P.
    DiPaola, Robert S.
    Haas, Naomi B.
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)
    Argiris, A.
    Lee, J. W.
    Stevenson, J.
    Sulecki, M. G.
    Hugec, V.
    Choong, N. W.
    Saltzman, J. N.
    Song, W.
    Hansen, R. M.
    Evans, T. L.
    Ramalingam, S. S.
    Schiller, J. H.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3037 - 3043
  • [45] Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)
    Patel, Jyoti D.
    Lee, Ju-Whei
    Carbone, David P.
    Wagner, Henry
    Shanker, Anil
    de Aquino, Maria Teresa P.
    Horn, Leora
    Johnson, Melissa L.
    Gerber, David E.
    Liu, Jane Jijun
    Das, Millie S.
    Al-Nsour, Mohammed Ali
    Dakhil, Christopher S. R.
    Ramalingam, Suresh
    Schiller, Joan H.
    CLINICAL LUNG CANCER, 2020, 21 (06) : 520 - 526
  • [46] A phase I trial of plinabulin in combination with nivolumab and ipilimumab in patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study.
    Malhotra, Jyoti
    Hanna, Nasser H.
    Chiappori, Alberto
    Feldman, Lawrence Eric
    Fujioka, Naomi
    Rybkin, Igor I.
    Jalal, Shadia Ibrahim
    Patel, Malini
    Moore, Dirk
    Chen, Chunxia
    Jabbour, Salma K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell CarcinomaA Trial of the ECOG-ACRIN Cancer Research Group (E2804)
    Flaherty, Keith T.
    Manola, Judith B.
    Pins, Michael
    McDermott, David F.
    Atkins, Michael B.
    Dutcher, Janice J.
    George, Daniel J.
    Margolin, Kim A.
    DiPaola, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (21) : 2384 - U88
  • [48] Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial.
    Argiris, Athanassios
    Li, Shuli
    Savvides, Panayiotis
    Ohr, James
    Gilbert, Jill
    Levine, Marshall A.
    Haigentz, Missak
    Saba, Nabil F.
    Chakravarti, Arnab
    Ikpeazu, Chukwuemeka
    Schneider, Charles
    Pinto, Harlan
    Forastiere, Arlene A.
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).
    Evens, Andrew M.
    Hong, Fangxin
    Habermann, Thomas Matthew
    Advani, Ranjana H.
    Gascoyne, Randy D.
    Witzig, Thomas E.
    Quon, Andrew
    Wagner, Lynne I.
    Ansell, Stephen Maxted
    Petrich, Adam Matthew
    Chang, Julie E.
    O'Brien, Timothy E.
    Cheema, Puneet S.
    Cescon, Terrence
    Sturtz, Keren
    Kahl, Brad S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
    Mezzanotte-Sharpe, Jessica
    ONeill, Anne
    Mayer, Ingrid A.
    Arteaga, Carlos L.
    Yang, Ximing J.
    Wagner, Lynne I.
    Cella, David
    Meropol, Neal J.
    Alpaugh, R. Katherine
    Saphner, Thomas J.
    Swaney, Robert E.
    Hoelzer, Karen L.
    Gradishar, William J.
    Abramson, Vandana G.
    Sundaram, P. Kothai
    Jilani, Shamim Z.
    Perez, Edith A.
    Lin, Nancy U.
    Jahanzeb, Mohammad
    Wolff, Antonio C.
    Sledge, George W.
    Reid, Sonya A.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, : 275 - 282
12345